|
|
Article: Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant.
- Article from:
- PR Newswire
- Article date:
- March 5, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-Company Provides Update on Cash Position-
-Biologics License Application for Wrinkles/Nasolabial Folds Indication Expected To Be Filed Within Two Weeks-
EXTON, Pa., March 5 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. announced today positive top-line efficacy results from a Phase II/III clinical study (Study IT-A-008) of the Isolagen Therapy(TM) for the treatment of moderate to severe acne scars. The study met all primary efficacy endpoints and was statistically significant, making this a major clinical milestone for the Company.
"This is very exciting, positive data which continues to support the potential of the Isolagen Therapy as a ...